ReviewFrontiers in immunology2026
The potential of platelet-rich plasma and PRP-derived biologics for neurological disorders: mechanisms and translational research.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet-rich plasma (PRP), an autologous blood derivative rich in multiple growth factors and cytokines, has shown broad application prospects in the field of tissue repair and regeneration. In recent years, the therapeutic potential of PRP in neurological disorders has gained increasing attention. This article systematically reviews the classification systems, preparation methods, and the molecular mechanisms and application progress of PRP in neural repair. In preclinical studies, PRP has been shown to release insulin-like growth factor-1 (IGF-1), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and transforming growth factor-β (TGF-β), which may synergistically activate PI3K/Akt and MAPK/ERK signaling pathways, suggesting potential tissue repair, axonal regenerative, angiogenic, and immunomodulatory effects. The three-dimensional fibrin scaffold formed upon platelet activation not only provides physical support for cell migration and axonal growth but also enables the sustained local release of growth factors. In central nervous system disorders, intrathecal PRP has shown potential in animal models to alleviate neuroinflammation after spinal cord injury(SCI), and intranasal administration can improve cognitive function and neurogenesis in Alzheimer's disease(AD) models. In peripheral nervous system disorders, local injection or PRP filling within nerve conduits significantly promotes regeneration and functional recovery after injuries to the sciatic nerve, facial nerve, and others. Furthermore, the therapeutic efficacy of PRP is influenced by factors such as preparation method, cellular composition (leukocyte content), administration route, and activation method. Although preclinical evidence is substantial, the clinical application of PRP in neurological disorders still faces challenges including a lack of standardization, unclear mechanisms, and the need to verify long-term safety. This review aims to provide a theoretical basis and practical reference for further research and clinical translation of PRP in the field of neural repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.